Abstract
Objective To investigate the relationship between genetic polymorphisms of RRM 1 and survival of patients with advanced non-small cell lung cancer(NSCLC) treated with gemcitabine based chemotherapy.Methods 40 cases treated with gemcitabine chemotherapy in patients with advanced non-small cell lung cancer,the branch DNA-liquid chip detection of RRM1 mRNA expression level,curative effect of gemcitabine in advanced lung cancer prediction.Results 23 patients with low expression of RRM1 (57.5％),high expression in 17 cases (42.5％),and low expression in patients with high expression of chemotherapy efficiency,time to disease progression was 78.2％,35.2％,12.4 months and 8.2 months,with a significant difference between two groups (P＜0.05).Conclusion The expression of RRM1 gene could be used to predict the chemotherapy index of advanced non-small cell cancer with gemcitabine platinum. Key words: Branch of the DNA-liquid chip technology; RRM1 ; non-small cell lung cancer
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
